Akèy › Maladi poumon
Etid klinik pou Maladi poumon ap rekrite nan Etazini
57 etid pou Maladi poumon ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX15 etid
- Boston, MA14 etid
- Durham, NC13 etid
- New York City, NY12 etid
- Nashville, TN10 etid
- Columbus, OH10 etid
- Miami, FL10 etid
- Pittsburgh, PA10 etid
- Los Angeles, CA10 etid
- Dallas, TX10 etid
- Washington, DC10 etid
- Ann Arbor, MI10 etid
- Birmingham, AL9 etid
- Chicago, IL9 etid
- Orlando, FL8 etid
- Philadelphia, PA8 etid
- Baltimore, MD8 etid
- Tampa, FL7 etid
- Seattle, WA7 etid
- Atlanta, GA7 etid
- Cincinnati, OH7 etid
- Detroit, MI7 etid
- Jacksonville, FL7 etid
- Charleston, SC7 etid
- St. Louis, MO6 etid
- Kansas City, KS6 etid
- Salt Lake City, UT6 etid
- Arlington, VA5 etid
- Oklahoma City, OK5 etid
- Indianapolis, IN5 etid
- Winston-Salem, NC5 etid
- San Francisco, CA5 etid
- Louisville, KY5 etid
- Hialeah, FL5 etid
- Portland, OR5 etid
- Newport Beach, CA4 etid
- Charlotte, NC4 etid
- Orange, CA4 etid
- Tucson, AZ4 etid
- Kansas City, MO4 etid
Pa eta
- Alabama13 etid
- Arizona9 etid
- Ayiti3 etid
- Colorado12 etid
- Distrik Columbia6 etid
- Florid26 etid
- Georgia11 etid
- Idaho3 etid
- Illinois16 etid
- Indiana5 etid
- Kalifòni30 etid
- Kansas9 etid
- Kentucky9 etid
- Lwizyàn5 etid
- Maryland13 etid
- Massachusetts15 etid
- Michigan17 etid
- Minnesota7 etid
- Missouri8 etid
- Nebraska4 etid
- Nevada6 etid
- New Jersey6 etid
- New Mexico3 etid
- New York16 etid
- North Carolina18 etid
- Ohio18 etid
- Oklahoma5 etid
- Oregon5 etid
- Pennsylvania20 etid
- Rhode Island3 etid
- South Carolina11 etid
- Tennessee15 etid
- Texas22 etid
- Utah7 etid
- Vermont4 etid
- Virginia10 etid
- Washington8 etid
- Wisconsin3 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06765109Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT01730092Study of the Disease Process of Lymphangioleiomyomatosis
Ap rekriteEtid obsèvasyon
Laj 16 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT00001465A Study of COVID-19 Vaccine(s) in Children and Adults
Ap rekriteFaz 3Volontè an sante akeyi
Laj 5 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07798648A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
Ap rekriteFaz 3
Laj 12 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06679140A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07013474Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07489066A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Ap rekriteFaz 2
Laj 40 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT07759245American Lung Association (ALA) Lung Health Cohort
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 25 a 35 · Tout sèks · Mizajou Sep 23, 2026 · NCT04543461Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06128551Study of Lung Proteins in Patients With Pneumonia
Ap rekriteEtid obsèvasyon
Laj 3 a 99 · Tout sèks · Mizajou Sep 22, 2026 · NCT00077909A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Sep 22, 2026 · NCT06977581A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07407933Role of Genetic Factors in the Development of Lung Disease
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 2 a 90 · Tout sèks · Mizajou Sep 10, 2026 · NCT00001532A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06119581A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06572384Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
Ap rekriteFaz 2
Laj 40 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT07059091Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
Ap rekriteFaz 3
Laj 40 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07284602A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
Ap rekriteFaz 2
Laj 18 a 85 · Tout sèks · Mizajou Sep 2, 2026 · NCT07333183A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 1, 2026 · NCT05967689Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT05624450A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 60 · Tout sèks · Mizajou Aug 27, 2026 · NCT07745907A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma
Ap rekriteFaz 2
Laj 4 a 11 · Tout sèks · Mizajou Aug 27, 2026 · NCT07525375Understanding New Cachexia Subtypes Through Observational Epidemiological Research
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT07776353A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Aug 11, 2026 · NCT07555483Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.